PROM1 and hepatocellular carcinoma: Accumulating evidence pointed out that cancer stem cells (CSCs), with verified stemness markers (eg. CD133, EpCAM, CD90, ALDH) [8, 9], might induce sorafenib resistance in HCC [10, 11] and are considered as novel therapeutic targets [12, 13].